Skip to main content

An open drawer of a telemedicine terminal in Des Moines, Iowa, from which Planned Parenthood of the Heartland clinic doctors can remotely prescribe the abortion-inducing drug RU-486, is shown on Sept. 22, 2010.

Charlie Neibergall/THE ASSOCIATED PRESS

The much-anticipated arrival of the abortion pill Mifegymiso in Canada has been delayed until the new year.

The drug's Canadian distributor, Celopharma Inc., says it now expects to launch "some time in January."

Company president Paula Tenenbaum gave few details in a terse email exchange but said it was related to "a change in manufacturing site."

Story continues below advertisement

Last month, Tenenbaum said Mifegymiso was on track for a November debut in Canada.

Health Canada approved the drug in July with several controversial restrictions, including that it only be dispensed by a doctor to a patient, which critics feared would restrict access for patients in rural and remote areas.

It's also limited to use no more than seven weeks after a woman's last period and comes with a steep $300 price tag.

The drug has been available elsewhere for nearly 30 years and is approved for use in more than 60 countries with varying restrictions.

Last month, Tenenbaum said Celopharma was working on a revised submission to Health Canada that would increase the recommended use to up to nine weeks after a woman's last menstrual period.

She also expressed her preference that pharmacists dispense the drug directly to patients.

Tenenbaum said Monday that she hoped to get a response from Health Canada "some time late December."

Story continues below advertisement

A spokesman for Health Canada said the federal agency does not disclose details about the status of drug approval applications, but "firmly supports a woman's right to choose."

"The department is committed to minimizing any undue delays in the review of any submission. Health Canada makes all drug approval decisions based on a detailed scientific review, and we continue to work with Celopharma on its application."

Mifegymiso is a combination of two drugs taken on separate days.

Mifepristone is taken first to block the hormone progesterone, which helps prepare the lining of the uterus for pregnancy. This causes the lining to break down and shed.

Then it's followed 24 to 48 hours later by misoprostol, which causes the uterus to contract and expel the pregnancy.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter